Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Chemomab Therapeutics Q3 EPS $(0.04) Beats $(0.33) Estimate

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.33) by 89.39 percent. This is a 86.54 percent increase over losses of $(0.26) per share
byBenzinga Newsdesk
November 11, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.33) by 89.39 percent. This is a 86.54 percent increase over losses of $(0.26) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Apple, Microsoft And Other Information Technology Stocks From Benzinga’s Most Accurate Analysts

By Lisa Levin
Today, 10:58 PM
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst's opinion to trust.

AAPL